Table 1 Drug resistance-related genes differentially expressed after MenSC coculture via epigenetic alterations
Genes | Expression after MenSC therapy | Epigenetic alteration after MenSC therapy | Expression in literature | Drug resistance |
|---|---|---|---|---|
ID4 | Downregulated | 5mC upregulation in the promoter 5-hmC downregulation in the enhancer | Upregulated | Glioma: 1,3-bis(2-chloroethyl)-1-nitrosourea |
SQSTM1 | Downregulated | 5-hmC downregulation in the promoter | Upregulated | Ovarian cancer: cisplatin Gastric cancer: cisplatin |
HMGA1 | Downregulated | 5mC upregulation in the enhancer 5-hmC downregulation in the enhancer | Upregulated | Lung cancer: tyrosine kinase inhibitor Ovarian cancer: paclitaxel, doxorubicin Sarcoma: trabectedin Cholangiocarcinoma: gemcitabine |
GATA2 | Downregulated | 5-mC upregulation in the enhancer 5-hmC downregulation in the enhancer | Upregulated | Prostate cancer: docetaxel, cabazitaxel |
PSAT1 | Downregulated | 5-hmC downregulation in the enhancer | Upregulated | Colorectal cancer: oxaliplatin Breast cancer: tamoxifen |
FASN | Downregulated | 5-hmC downregulation in the enhancer | Upregulated | Ovarian cancer: cisplatin Lung cancer: tyrosine kinase inhibitor Gastrointestinal stromal tumor: imatinib Triple-negative breast cancer: cetuximab |